TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES ET 9:00 a.m: Fed's Barr speaks, 10:00 a.m: US July Wholesale Inventories, 1:00 p.m: Baker Hughes US Rig Count, 3:00 p.m: US July Consumer Credit TODAY’S HIGHLIGHTS: NFL Fans Mocked Cris Collinsworth For His Take on Patrick Mahomes’s GreatnessWidespread outage leaves Cash
Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight’ rating and a $5 price target on their.
Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, a drug.
Atossa Therapeutics Inc (NASDAQ:ATOS) President & CEO Dr. Steven Quay joins Thomas Warner from Proactive to speak about the latest developments in his and.
Atossa Therapeutics (NASDAQ:ATOS) Earns Sell Rating from Analysts at StockNews com defenseworld.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from defenseworld.net Daily Mail and Mail on Sunday newspapers.